HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EZN 3042

a locked nucleic acid antisense oligonucleotide against survivin

Also Known As:

EZN-3042; EZN3042

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - EZN 3042: 4

Experts

1.	Joseph, Jenette K: 1 article (03/2020)
2.	Meuten, Travis K: 1 article (03/2020)
3.	Rose, Barbara J: 1 article (03/2020)
4.	Thamm, Douglas H: 1 article (03/2020)
5.	Weishaar, Kristen M: 1 article (03/2020)
6.	Charles, J B: 1 article (06/2016)
7.	Ehrhart, E J: 1 article (06/2016)
8.	Shoeneman, J K: 1 article (06/2016)
9.	Thamm, D H: 1 article (06/2016)
10.	Bhojwani, Deepa: 1 article (08/2014)

Related Diseases

1.	Neoplasms (Cancer) 03/24/2020 - "This dose may be used in future studies of EZN-3042/chemotherapy combinations in dogs with spontaneous lymphoma and other cancers." 06/01/2016 - "Our findings strongly suggest that survivin-directed therapies might be effective in treatment of canine LSA and OS and support evaluation of EZN-3042 in dogs with cancer. " 02/01/2010 - "In A549 and Calu-6 lung xenograft models, treatment with EZN-3042 single agent induced 60% down-modulation of survivin mRNA in tumors and 37-45% tumor growth inhibition (TGI). " 02/01/2010 - "Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide."
2.	Lymphoma (Lymphomas) 03/24/2020 - "Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma." 03/24/2020 - "In conclusion, reduced survivin expression was demonstrated in lymphoma tissues in the majority of dogs treated with EZN-3042 at 8.25 mg/kg twice weekly, which was associated with minimal adverse effects. " 03/24/2020 - "This dose may be used in future studies of EZN-3042/chemotherapy combinations in dogs with spontaneous lymphoma and other cancers." 06/01/2016 - "Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma." 03/24/2020 - "The goal of the current study was to determine the safety and pharmacodynamic effects of systemic administration of the anti-survivin locked nucleic acid antisense oligonucleotide EZN-3042 in dogs with lymphoma. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/01/2014 - "To address the therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042, with reinduction chemotherapy was developed for pediatric patients with second or greater bone marrow relapses of B-lymphoblastic leukemia. " 08/01/2014 - "A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium."
4.	Leukemia 08/01/2014 - "A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium."
5.	Osteosarcoma (Osteogenic Sarcoma) 06/01/2016 - "Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma."

Related Drugs and Biologics

1.	Survivin
2.	Antisense Oligonucleotides
3.	Messenger RNA (mRNA)
4.	locked nucleic acid
5.	RNA (Ribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)